Trastuzumab changes HER+ MBC
prognosis
OS probablility
Months since diagnosis
HER2-normal
HER2-positive with trastuzumab
HER2-positive without trastuzumab
Dawood et al. J Clin Oncol 2010;28:92–98
0,0
0,2
0,4
0,6
0,8
1,0
0
12
24
36
48
60
CCM = cáncer de mama metastásico
